Asia-Pacific Drug Discovery Market: Revenue Expected to Grow with a CAGR of 8.67% During the Forecasted Years, 2019-2027 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Asia-Pacific Drug Discovery Market 2019-2027” report has been added to ResearchAndMarkets.com’s offering.

Market Outlook

As per this Market Research report, the Asia-Pacific drug discovery market is showcasing steady growth at a CAGR of 8.67% over the forecasted years 2019-2027 in terms of revenue.

China, Japan, India, South Korea, Australia, and Rest of APAC are the countries that form the drug discovery market in the region.

The Asia-Pacific region is predicted to be the fastest-growing region in the drug discovery market during the forecasted period. Different healthcare organizations across the globe have been planning to set up businesses in Asian countries. The rising technological innovations and the application of small molecule drugs for treating chronic disorders are primarily fueling the demand for various drugs. This is expected to boost the drug discovery market in the Asia-Pacific.

In South Korea, several contract research organizations (CROs) are actively working in ongoing drug discovery programs, such as those for curing various types of cancer, neurological & metabolic diseases, and bacterial infections. For instance, the new anti-cancer drug has been developed with Bionetix, a South Korean biotechnology company, through its collaborative research programs. Also, Celerion and the Korean Drug Development Fund (KDDF) have made a partnership to support the development of the drug discovery market in South Korea. Moreover, many new approaches considering proteomics, genomics and bioinformatics technologies have been developed, which would offer lucrative opportunities for the growth of the drug discovery market.

Key Topics Covered:

1. Asia-Pacific Drug Discovery Market – Summary

2. Industry Outlook

2.1. Market Definition

2.2. Porter’s Five Forces Model

2.2.1. Threats of New Entrants

2.2.2. Threat of Substitute Products

2.2.3. Bargaining Power of Buyers

2.2.4. Bargaining Power of Suppliers

2.2.5. Competitive Rivalry

2.3. Pestle Outlook

2.4. Regulatory Framework

2.5. Value Chain Outlook

2.6. Market Attractiveness Index

2.7. Key Insight

2.8. Market Drivers

2.8.1. Growing Aged Population

2.8.2. Technological Advancements

2.8.3. Rise in the Healthcare Expenditure

2.8.4. Surge in Lifestyle-Oriented Diseases

2.9. Market Restraints

2.9.1. Delay in Product Launches

2.9.2. Restricting Growth Rate of A Drug Due to Generic Drugs

2.10. Market Opportunities

2.10.1. Significant Investment By Healthcare Industries in Improving Big-Data Analytical Capabilities

2.10.2. Rising Demand for Specialty Medicines

2.11. Market Challenges

2.11.1. Poor Reimbursements Policies in Emerging Nations

2.11.2. Stringent Government Regulations

3. Drug Discovery Market Outlook – By Drug Type

3.1. Small Molecule Drug

3.2. Biologic Drug

4. Drug Discovery Market Outlook – By Technology

4.1. High Throughput Screening

4.2. Biochips

4.3. Bioinformatics

4.4. Pharmacogenomics and Pharmacogenetics

4.5. Combinatorial Chemistry

4.6. Nanotechnology

4.7. Spectroscopy

4.8. Metabolomics

4.9. Other Technologies

5. Drug Discovery Market Outlook – By Service

5.1. Drug Metabolism and Pharmacokinetics (Dmpk) Services

5.2. Chemical Services

5.3. Biological Services

5.4. Other Pharmaceutical Services

6. Drug Discovery Market Outlook – By End-User

6.1. Research Institutes

6.2. Pharmaceutical Companies

6.3. Contract Research Organizations (Cros)

6.4. Other End-Users

7. Drug Discovery Market – Regional Outlook

7.1. Asia-Pacific

7.1.1. Country Analysis

7.1.1.1. China

7.1.1.2. India

7.1.1.3. Japan

7.1.1.4. South Korea

7.1.1.5. Australia & New Zealand

7.1.1.6. Asean Countries

7.1.1.7. Rest of Asia-Pacific

8. Company Profiles

8.1. 3M Company

8.2. Abbott Laboratories Inc.

8.3. Agilent Technologies, Inc.

8.4. Antares Pharma

8.5. Astrazeneca Plc

8.6. Bayer Ag

8.7. Becton, Dickinson and Company (Bd)

8.8. Boehringer Ingelheim

8.9. Eli Lily and Company

8.10. F. Hoffmann-La Roche Ltd.

8.11. Glaxosmithkline Llc

8.12. Johnson & Johnson

8.13. Merck & Co., Inc.

8.14. Novartis

8.15. Pfizer, Inc.

8.16. Sanofi

9. Research Methodology & Scope

9.1. Research Scope & Deliverables

9.1.1. Objectives of Study

9.1.2. Scope of Study

9.2. Sources of Data

9.2.1. Primary Data Sources

9.2.2. Secondary Data Sources

9.3. Research Methodology

9.3.1. Evaluation of Proposed Market

9.3.2. Identification of Data Sources

9.3.3. Assessment of Market Determinants

9.3.4. Data Collection

9.3.5. Data Validation & Analysis

For more information about this report visit https://www.researchandmarkets.com/r/w7xkhy

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900